Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations - Wikidata - wikimedia - TriplyDB

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

http://www.wikidata.org/entity/Q35034349

about

Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study)Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.Protease inhibitor-associated QT interval prolongation.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products Prolongation of the QTc interval in HIV-infected individuals compared to the general population.Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons.Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation.Effects of HIV Protease Inhibitors on Cardiac Conduction Velocity in Unselected HIV-Infected Patients

P2860

Q30362434-D2FF4E17-77EA-43D6-A25B-481348209F95 Q33649200-35A62CFF-58F5-4BF9-AD8F-4C2D3EEC4822 Q35289501-6AA52301-DF43-4D55-B55D-A53A711547EC Q35867385-5788AC21-FCDE-4B06-A44C-ADA638EB9DDD Q36476523-AAD8FDD8-F329-442B-85D7-1FE811B3E356 Q36941650-B4327C82-0032-434D-A920-0FA9533608FE Q37962886-8E62A248-41F5-4219-BBF0-1A66D15D5BDC Q38513275-1FB43069-B24E-490F-973A-CE104B5A0AF8 Q40095042-90E276B0-183D-4214-A392-5E3A6ECF2CB5 Q40566104-0ADCFE4E-33CE-4C84-A757-51980C9E3F88 Q42990255-79E9C9AD-99D8-46E5-A15D-E774072CA0CC Q57314065-B2285EC9-F320-42B8-97C6-9751AE5C80BF

P2860

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

http://www.wikidata.org/entity/Q35034349

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@ast

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@en

type

label

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@ast

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@en

prefLabel

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@ast

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@en

P1433

Q35034349-1AAA2EEC-29C2-48D8-83C1-E66A1AFEBBBB

P1476

Q35034349-0BA8B7EE-0D2D-40B7-94FA-D54DCB4122AA

P2093

Q35034349-18BF5DC6-0E22-4E1A-8C50-21A4D63DE8A9

Q35034349-343BEF13-5304-47DD-B286-263252F18730

Q35034349-515D6461-6CAA-44A1-BD53-747809B6F8C9

Q35034349-533405B6-3187-4951-9AD3-881DD3A5F250

Q35034349-5B8E0AD8-6E1D-412C-863A-D769DA8E7437

Q35034349-6E35277B-2683-4FE7-9188-20B657E45945

Q35034349-720DD0C3-8674-4044-A7EF-46C553573985

Q35034349-7856C58E-0364-40B9-98A5-53C4E0B67433

Q35034349-9B149633-D6DD-4E26-A3F1-D713065FC41F

Q35034349-DEBE2D0F-FCBE-403B-ABE9-67BA02DDFC36

P2860

Q35034349-04F8493E-D527-4B0B-969D-2E4CF77AFFA7

Q35034349-1C34A164-D7A7-4722-9755-9D1328283EA7

Q35034349-383E7CAC-58A2-4962-B16E-8E0CD80D683F

Q35034349-391B501C-7C42-43D3-B0EF-EAF7CC9C8A63

Q35034349-40FA7589-63E2-4347-8CBB-74F59C9AB62A

Q35034349-52E5C09F-68F2-41CE-8010-3D4F2719D6DC

Q35034349-83BB3FE7-70C5-4BCC-92D4-C96EBAF36AA4

Q35034349-8A3FADAB-F2E1-4A5C-B3A8-7AA377906954

Q35034349-AE8806D6-3761-4AFF-88AB-9DB0FF1DB4E3

Q35034349-BE7E1487-3C5A-48F0-BEA4-9DCBA232F258

P304

Q35034349-669020A0-3509-4EF0-A2A3-C5B5AFCFCA78

P31

Q35034349-DC3321EA-1418-4051-A367-22C7E7FDB936

P356

Q35034349-B85DC754-9852-47E1-85B2-963554B892D2

P407

Q35034349-1D422B8B-D3F6-44A0-8F70-4239570676B7

P433

Q35034349-207E63CF-B52E-44F8-8BDB-D7B836392B5A

P478

Q35034349-33EC14F5-FAEF-4C69-B4F4-254D31FE273B

P50

Q35034349-186041DA-83C6-4937-A6EB-D60F0DD20B0A

Q35034349-22137B1E-E22E-4794-8D9A-F638BA92D553

P577

Q35034349-6572E53D-583F-42CA-8157-495274379FAE

P698

Q35034349-930BDB22-32B8-4751-BF7D-4084DCAE5547

P921

Q35034349-8A01A663-8144-44BC-B291-901F16C0CC04

P932

Q35034349-A1CB2573-025B-4F73-B5D4-5699476CB876

P356

QAD.0B013E328341DCC0

P1433

P1476

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

@en

P2093

Charurut Somboonwit

http://www.w3.org/2001/XMLSchema#string

Daniel A Duprez

http://www.w3.org/2001/XMLSchema#string

Elsayed Z Soliman

http://www.w3.org/2001/XMLSchema#string

INSIGHT SMART Study Group

http://www.w3.org/2001/XMLSchema#string

James D Neaton

http://www.w3.org/2001/XMLSchema#string

Judith C Shlay

http://www.w3.org/2001/XMLSchema#string

Markus Bickel

http://www.w3.org/2001/XMLSchema#string

Mollie P Roediger

http://www.w3.org/2001/XMLSchema#string

Peter Reiss

http://www.w3.org/2001/XMLSchema#string

Zelalem Temesgen

http://www.w3.org/2001/XMLSchema#string

P2860

CD4+ count-guided interruption of antiretroviral treatment

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study

Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval.

HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Prolonged QT interval and torsades de pointes associated with atazanavir therapy.

Sudden death associated with short-QT syndrome linked to mutations in HERG.

Relationships between heart rate and PR interval during physiological and pharmacological interventions.

Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study

Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study.

P304

367-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E328341DCC0

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21150558

http://www.w3.org/2001/XMLSchema#string

P921

electrocardiography

P932

3111078

http://www.w3.org/2001/XMLSchema#string